Simcere Zaiming (a subsidiary of China's Simcere Pharmaceutical Group) announced Wednesday September 2, 2026 an exclusive global licensing agreement with Roche for SIM0660, a T-cell engager tri-specific antibody targeting CD79a, CD19, and CD3 for B-cell-mediated diseases. Deal terms: $75 million upfront plus up to $1.53 billion in total development, regulatory, and commercial milestone payments plus tiered royalties up to double-digits on future net sales. Roche acquires exclusive global rights to develop, manufacture, and commercialize SIM0660. The molecule combines a CD3-engaging arm with binding domains targeting the two B-cell antigens CD79a and CD19 to induce T-cell-mediated cytotoxicity while limiting cytokine release, positioned to compete with the emerging poly-specific antibody category (Amgen tarlatamab, Regeneron REGN5459, Janssen amivantamab). The transaction is the latest in a $60+ billion H1 2026 wave of China-to-multinational biotech licensing that continues to feed U.S. and European pharma pipelines.
Inventiva SA (NASDAQ: IVA) announced Wednesday September 2, 2026 completion of the last patient's final 72-week visit in the Phase 3 NATiV3 study of lanifibranor (a pan-PPAR α/δ/γ agonist) in adults with biopsy-proven non-cirrhotic MASH and F2/F3 fibrosis. Enrollment: 1,009 patients in the main cohort plus an additional 410 patients in the exploratory cohort. NATiV3 assesses lanifibranor on histological endpoints including MASH resolution and improvement of fibrosis of at least one stage after 72 weeks of treatment. Inventiva expects to report topline data in Q4 2026 with NDA filing planned for H1 2027. Lanifibranor differentiates from the standard-of-care Madrigal Rezdiffra (resmetirom, THR-β agonist, approved March 2024) plus the emerging Boehringer Ingelheim survodutide, Novo Nordisk semaglutide MASH, and Akero Therapeutics efruxifermin (FGF21) programs by engaging three complementary PPAR isoforms in parallel to address steatosis, inflammation, and fibrosis.
Analytics firm GlobalData published Wednesday September 2, 2026 a myasthenia gravis (MG) market forecast projecting the seven-major-markets (7MM: United States, France, Germany, Italy, Spain, United Kingdom, Japan) MG treatment market to grow from $4.5 billion in 2024 to $13.0 billion in 2034 at an 11.1% CAGR, driven by launches and label expansions in the anti-FcRn class (argenx Vyvgart Hytrulo, Johnson & Johnson Imaavy nipocalimab), complement inhibitors (Alexion/AstraZeneca Ultomiris, Soliris), and BAFF/BLyS-targeting therapies (Cytokinetics aficamten in adjacent indications). The forecast supports the ongoing peptide-therapeutic case in autoimmune indications where synthetic peptide-vaccine and peptide-immunomodulator approaches (thymalfasin, thymosin analogs) are being evaluated as adjuncts to the biologics-first standard-of-care. Anti-FcRn represents the fastest-growing MG segment given the manageable safety profile and infrequent dosing versus the plasmapheresis and IVIG protocols that dominated the pre-Vyvgart era.
Ultragenyx Pharmaceutical (NASDAQ: RARE) awaits its September 19, 2026 PDUFA target action date for UX111 (rebisufligene etisparvovec, an AAV9 gene therapy delivering the SGSH gene) for the treatment of Sanfilippo syndrome type A (mucopolysaccharidosis type IIIA, MPS IIIA, a rare autosomal recessive lysosomal storage disorder caused by SGSH gene mutations that results in progressive cognitive decline in early childhood and death typically by the second decade). If approved, UX111 would become the first FDA-approved therapy for MPS IIIA, where the current standard of care remains supportive symptom management. The AAV9-based intravenous delivery approach mirrors the Novartis Zolgensma (onasemnogene abeparvovec) commercial template for spinal muscular atrophy and continues the neurometabolic gene therapy pipeline. Not a peptide, but the approval would extend the AAV gene therapy commercial category that has continued to reshape the rare-disease landscape alongside enzyme replacement therapies and the emerging small-molecule chaperone class.
Ionis Pharmaceuticals (NASDAQ: IONS) awaits its September 22, 2026 PDUFA target action date for zilganersen (an intrathecally-administered antisense oligonucleotide designed to reduce production of glial fibrillary acidic protein / GFAP) for the treatment of Alexander disease, a rare autosomal dominant neurodegenerative disease caused by GFAP gene mutations. If approved, zilganersen would become the first FDA-approved therapy for Alexander disease and Ionis's next commercial launch following Wainua (eplontersen) for hereditary transthyretin amyloid polyneuropathy (with the CARDIO-TTransform ATTR-CM primary endpoint miss now behind the company). Zilganersen was granted FDA Fast Track designation and Orphan Drug designation. Alexander disease presents in infancy through adulthood with progressive motor and cognitive decline; no disease-modifying therapies are currently approved. Not a peptide, but the antisense oligonucleotide class continues to complement peptide-based rare-disease therapies (Rein Therapeutics LTI-03 Caveolin-1 peptide for IPF among others) as the RNA modality expands into ultra-orphan indications.
Novartis (NYSE: NVS) shares rose more than 4% Tuesday September 1 and continued climbing Wednesday September 2, 2026 following the twin REMODEL-1 and REMODEL-2 Phase 3 wins of remibrutinib (an oral BTK inhibitor) in relapsing multiple sclerosis, which met both primary endpoints versus teriflunomide with a clean liver-safety profile across the 4,500+ patient program. Investor focus now turns to two additional Novartis growth-vehicle programs: pacibekitug (an anti-IL-6 monoclonal antibody acquired in the $1.4 billion Tourmaline Bio acquisition earlier in 2026) advancing into Phase 3 for cardiovascular risk reduction despite Novo Nordisk's ZEUS ziltivekimab Phase 3 miss at ESC 2026 last weekend; and the ongoing integration of the $12 billion Avidity Biosciences acquisition centered on RNAi drug delivery to muscle tissue for facioscapulohumeral muscular dystrophy, DM1 myotonic dystrophy, and Duchenne muscular dystrophy programs. Novartis Q3 2026 earnings release is scheduled for late October.
Novartis (NYSE: NVS) announced Tuesday September 1, 2026 that the twin REMODEL-1 and REMODEL-2 Phase 3 trials of remibrutinib (an oral, selective, high-efficacy Bruton's tyrosine kinase inhibitor) met both primary endpoints in relapsing multiple sclerosis, with remibrutinib demonstrating statistically significant superiority versus teriflunomide (Aubagio) in reducing annualized relapse rate (ARR) and inflammatory brain MRI lesions. Key secondary endpoints related to disability progression trended in favor of remibrutinib, with nominal significance in 6-month confirmed disability progression (6mCDP) in a preplanned pooled analysis. Safety was clean: no liver-safety signal and no cases meeting Hy's Law criteria across a broader remibrutinib development program that has now enrolled more than 4,500 participants across neurologic and immune-mediated indications. Full REMODEL-1/-2 data will be presented at MSToronto2026 (ECTRIMS-ACTRIMS joint meeting, October 21-23, Toronto). Regulatory submissions will follow. The readout positions remibrutinib as a potential oral option in a category currently anchored by injectable anti-CD20 therapies (Ocrevus, Kesimpta, Briumvi) plus Sanofi's Aubagio and the sphingosine-1-phosphate receptor modulators.
Alumis (NASDAQ: ALMS) announced Tuesday September 1, 2026 that the Phase 2b LUMUS trial of envudeucitinib (an oral allosteric TYK2 inhibitor designed to correct immune dysregulation across IL-23, IL-17, and Type I interferon pathways) failed to meet the primary endpoint of British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response at Week 48 in patients with systemic lupus erythematosus (n=408). All secondary objectives also missed. Strong responses were observed in the pre-specified high-interferon-gene-signature subgroup (which characterizes a majority of moderate-to-severe SLE patients), but IFNGS-high patients were under-represented in the overall trial population which reduced the treatment effect. Alumis (ALMS) shares fell approximately 55% and erased more than $1.6 billion of market capitalization. The company will meet with regulators to discuss a Phase 3 SLE path targeting the IFNGS-high subgroup and remains on track to submit the envudeucitinib NDA for moderate-to-severe plaque psoriasis in Q4 2026 following the Phase 3 ONWARD program win.
RedHill Biopharma (NASDAQ: RDHL) announced Tuesday September 1, 2026 an exclusive global commercialization license for Rebyota (fecal microbiota, live-jslm) and an exclusive U.S. commercialization license for Clenpiq (sodium picosulfate, magnesium oxide, and citric acid oral solution for colonoscopy bowel preparation) from Ferring Pharmaceuticals, for an upfront payment of $12 million plus tiered royalties on net sales and potential milestones. Rebyota is the first-in-class FDA-approved microbiota-based therapy for the prevention of recurrent Clostridioides difficile infection in adults 18+ following antibiotic treatment (approved November 2022), generating approximately $16.9 million in 2025 U.S. net sales. The two products collectively generated approximately $37.5 million in 2025 U.S. net sales. Ferring retains Rebyota manufacturing and continues supply under the agreement. Not a peptide, but the transaction matters for the peptide-microbiome intersection: RedHill's expanded GI franchise now anchors the microbiome-therapy category alongside Vedanta's VE303, Seres Therapeutics' VOWST/SER-109, and the emerging peptide-antimicrobial and postbiotic categories.
Corbus Pharmaceuticals (NASDAQ: CRBP) confirmed Tuesday September 1, 2026 that the CANYON-1 Phase 1b topline data readout for CRB-913 (a once-daily orally-administered highly peripherally-restricted CB1 inverse agonist for obesity) remains on track for September 2026, following completion of the last patient last visit announced August 4. The CANYON-1 study is a 16-week double-blind placebo-controlled dose-ranging trial in 240 obese non-diabetic U.S. adults testing once-daily oral doses of 20 mg, 40 mg, and 60 mg versus placebo with dose titration and 4-week safety follow-up. CRB-913 is engineered to remain peripheral (approximately 15-fold lower brain penetration than the CB1 inverse agonist monlunabant in preclinical models) to preserve efficacy while limiting the psychiatric side effects that led to the withdrawal of Sanofi's Acomplia (rimonabant) in 2008. The mechanism is designed to complement or serve as an alternative to GLP-1 receptor agonists, and the CANYON-1 tolerability profile will determine whether Corbus advances CRB-913 into Phase 2 later in 2026.
BioVie Inc. (NASDAQ: BIVI) announced Monday August 31, 2026 completion of the last on-treatment visit in the ADDRESS-LC Phase 2 trial evaluating Bezisterim (a small-molecule insulin-sensitizer developed for the treatment of neurological symptoms of Long COVID). The Phase 2 study enrolled approximately 200 patients to evaluate whether Bezisterim can reduce brain fog, fatigue, and other lingering neurological symptoms after SARS-CoV-2 infection, and is fully funded by a grant from the U.S. Department of War (formerly Department of Defense). With the last patient's treatment visit complete and the one-month virtual follow-up nearly complete, BioVie anticipates topline results before end of September 2026. Not a peptide, but the readout is relevant to the peptide-industry Long COVID pipeline (LSALT peptide, BPC-157 for post-viral inflammation) and reflects the broader Department of War / BARDA interest in post-acute infection syndrome treatments.
Lexicon Pharmaceuticals (NASDAQ: LXRX) presented Monday August 31, 2026 at ESC Congress 2026 Munich a post-hoc analysis of the Phase 3 SOLOIST-WHF trial of sotagliflozin (INPEFA, a dual SGLT1/SGLT2 inhibitor) evaluating efficacy and safety across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure. The analysis was simultaneously published in JACC: Heart Failure (DOI 10.1016/j.jchf.2026.103368). Results: sotagliflozin's cardiovascular death and heart-failure-related event reduction was maintained regardless of baseline systolic blood pressure, including in patients with baseline SBP as low as 100 mmHg, without an increase in hypotension or acute kidney injury. The subgroup analysis strengthens the SGLT1/SGLT2 inhibitor commercial case in worsening heart failure where the class has historically been under-utilized due to concerns about hemodynamic tolerability in lower-blood-pressure patients.
Enveda Biosciences (Boulder, Colorado, AI-enabled natural product discovery platform) reported positive Phase 1 results August 18, 2026 for ENV-308, a first-of-its-kind oral small molecule engineered to mimic the therapeutic effects of Lac-Phe (a hormone released during intense exercise) for the treatment of post-GLP-1 weight regain and lean-mass loss. In the Phase 1 trial (n=88 healthy volunteers), ENV-308 was extremely well tolerated including on gastrointestinal safety, and reduced circulating leptin as an exploratory metabolic-engagement signal. In animal studies, ENV-308 preserved lean muscle during weight loss and prevented weight regain after weight-loss therapy was stopped. Enveda cites the statistic that 1 in 8 U.S. adults use GLP-1 medications and the majority who take them for weight loss stop within one year. Phase 2 will test whether ENV-308 can help people maintain weight after stopping GLP-1s. Not a peptide, but the exercise-mimetic pathway is one of the leading commercial answers to the muscle-preservation and post-discontinuation regain problems that constrain the current peptide obesity therapeutic class.
Novo Nordisk (NYSE: NVO) announced at ESC Congress 2026 that its Phase 3 ZEUS trial of ziltivekimab (an anti-IL-6 monoclonal antibody in development for cardiovascular risk reduction in inflammation-driven disease) failed to reduce major adverse cardiovascular events (MACE) versus placebo in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and inflammation (hsCRP ≥2 mg/L). The three-component MACE primary endpoint hazard ratio was 0.99 (95% CI 0.88-1.11), despite confirmed IL-6 pathway engagement (reductions in free IL-6 and hsCRP as expected). Safety was broadly similar between arms though serious infections were more frequent on ziltivekimab (consistent with the IL-6 class). NVO shares fell more than 9% on the readout, deepening the widening H1 2026 GLP-1 revenue gap that already sat at $10.2 billion versus Eli Lilly. Novo has committed to continuing the two other cardiovascular outcomes trials (HERMES in heart failure, ARTEMIS post-acute MI) with H1 2027 readouts. The ZEUS miss casts doubt on the broader thesis of anti-inflammatory cardiovascular risk reduction via IL-6 blockade.
The Factor XIa inhibitor milvexian (an oral small-molecule antithrombotic co-developed by Bristol Myers Squibb (NYSE: BMY) and Janssen) failed to reduce major adverse cardiovascular events versus placebo when added to standard antiplatelet therapy after recent acute coronary syndrome (ACS) in the Phase 3 LIBREXIA ACS trial presented in a Hot Line Session at ESC Congress 2026 Saturday August 29. The primary endpoint (cardiovascular death, myocardial infarction, or ischemic stroke) occurred in 5.4% of the milvexian arm versus 5.1% on placebo. Researchers observed no differences in intracranial or fatal bleeding between arms, addressing safety concerns that have historically constrained anticoagulant use in the post-ACS setting. The LIBREXIA program continues to assess milvexian in stroke and atrial fibrillation. The Factor XIa class as a whole (also including Bayer-Janssen's asundexian and Anthos Therapeutics' abelacimab) has struggled to demonstrate clean cardiovascular benefit at low bleeding cost.
The STAREE trial (a double-blind Australian primary-prevention trial in adults 70 and older) presented Saturday August 29, 2026 at ESC Congress 2026 Munich and simultaneously published in NEJM showed atorvastatin 40 mg daily reduced major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, stroke, or coronary revascularization) by approximately 30% versus placebo over 5.9 years median follow-up in 9,971 participants (mean age 74.7, 52% women). The co-primary endpoint of disability-free survival (survival free of dementia and physical disability) did not reach statistical significance. Muscle, liver, and diabetes-related adverse events were more common on atorvastatin, though serious adverse events were balanced. STAREE addresses a long-standing evidence gap on statin efficacy in older adults without known cardiovascular disease, diabetes, or dementia. Not a peptide, but the trial matters for peptide-industry readers because it reframes the primary-prevention benefit-risk calculus that will need to be modeled for cardiovascular outcome trials of peptide obesity therapies in older populations.
Novartis (NYSE: NVS) reiterated at ESC Congress 2026 Saturday August 29 that it will advance the Phase 3 program for pacibekitug (an anti-IL-6 monoclonal antibody acquired from Tourmaline Bio through the $1.4 billion acquisition completed earlier in 2026) for cardiovascular risk reduction in inflammation-driven disease, notwithstanding the Phase 3 ZEUS trial failure of Novo Nordisk's ziltivekimab announced the same weekend. Novartis's stance is that ZEUS was underpowered in the specific ASCVD-plus-CKD-plus-inflammation subgroup rather than a class-level miss for IL-6 blockade, and that pacibekitug's differentiated pharmacokinetic profile (longer half-life and less frequent dosing) plus the differently-selected patient population in the planned Phase 3 will allow the mechanism to prove out. The commitment is a $1.4 billion acquisition-scale bet against the base-rate signal from ZEUS and continues the pattern of large pharma anti-inflammatory cardiovascular pipeline commitment following the earlier successful CANTOS canakinumab (IL-1β) proof of concept.
AbCellera Biologics (NASDAQ: ABCL) announced Wednesday August 12, 2026 the pricing of an oversubscribed underwritten public offering of 17,435,897 common shares at $9.75 per share and pre-funded warrants to purchase up to 3,076,926 shares at $9.74999 per pre-funded warrant, for aggregate gross proceeds of approximately $200 million. Net proceeds of approximately $187 million are targeted to advance clinical development of lead program ABCL635 (an antibody-based candidate for vasomotor symptoms of menopause and related endocrine indications) plus additional immunology and oncology candidates. The offering closed August 14. AbCellera is a clinical-stage biotechnology company focused on discovering first-in-class antibody-based medicines in endocrinology, women's health, immunology, and oncology using its integrated antibody-discovery platform. Not a peptide company, but the offering is included here because AbCellera's platform overlaps with peptide-discovery approaches in the same discovery-to-clinical translation ecosystem, and the H2 2026 biotech financing window (which has already delivered Parabilis's $670M peptide IPO, Kardigan's $400M+ cardio IPO, and now AbCellera's $200M follow-on) reflects continued institutional appetite for platform-derived biologics.